FOSUN PHARMA (600196.SH) Latest Stock News - Major News Analysis - Longbridge

Quote List Quote List

Event Tracking

Dec3

Fosun Pharma Receives NMPA Approval to Initiate Clinical Trials for Anti-Cancer Drug FXS887

08:32

Dec2

Shanghai Fosun Pharma's subsidiary drug registration application accepted

12:45

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Heparin Sodium Injection Drug Registration Application

09:50

Nov28

Fosun Pharma Announces Pricing Basis and Policy for Medical Services

13:58

Nov21

Fosun Pharma's Lumovemetinib for LCH in Children Receives Priority Review for New Indication

09:28

Nov20

Fosun Pharmaceutical's Subsidiary's Sulrizumab Injection Included in Breakthrough Therapy Program

08:44

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(CST)

FY2025 Q3 Earning Release (CNY) Revenue 9.879 B, Net Income 821.33 M, EPS 0.3099

Aug26

Earning Release(CST)

FY2025 Q2 Earning Release (CNY) Revenue 10.09 B, Net Income 937.21 M, EPS 0.3495

Aug4

Distribution Plan(CST)

Cash dividend 0.32 CNY

View More

Stock List

Top Gainers

Top Decliners

Northbound Connect

Symbol

Price

%Chg

Change

View More